Compare · GKOS vs WST
GKOS vs WST
Side-by-side comparison of Glaukos Corporation (GKOS) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GKOS and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $23.34B, about 3.2x GKOS ($7.30B).
- Over the past year, GKOS is up 25.3% and WST is up 47.5% - WST leads by 22.2 points.
- GKOS has been more active in the news (11 items in the past 4 weeks vs 5 for WST).
- GKOS has more recent analyst coverage (25 ratings vs 17 for WST).
- Company
- Glaukos Corporation
- West Pharmaceutical Services Inc.
- Price
- $124.22+1.26%
- $330.47-0.10%
- Market cap
- $7.30B
- $23.34B
- 1M return
- -8.91%
- +5.84%
- 1Y return
- +25.26%
- +47.48%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2015
- News (4w)
- 11
- 5
- Recent ratings
- 25
- 17
Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest GKOS
- Glaukos Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Wen Leana was granted 1,878 shares, increasing direct ownership by 10% to 21,617 units (SEC Form 4)
- Director Weisner Aimee S was granted 1,878 shares, increasing direct ownership by 10% to 20,684 units (SEC Form 4)
- Director Torres Denice was granted 1,878 shares, increasing direct ownership by 8% to 24,212 units (SEC Form 4)
- Director Foley Mark J was granted 1,878 shares, increasing direct ownership by 3% to 60,267 units (SEC Form 4)
- Director Hoffmeister David F was granted 1,878 shares, increasing direct ownership by 4% to 49,549 units (SEC Form 4)
- Director Kliman Gilbert H was granted 1,878 shares, increasing direct ownership by 5% to 37,406 units (SEC Form 4)
- Director Stapley Marc was granted 1,878 shares, increasing direct ownership by 5% to 39,327 units (SEC Form 4)
- SEC Form SD filed by Glaukos Corporation
- Director Hoffmeister David F exercised 15,000 shares at a strike of $24.69, increasing direct ownership by 46% to 47,671 units (SEC Form 4)
Latest WST
- West Pharm upgraded by Barclays with a new price target
- Wolfe Research resumed coverage on West Pharm with a new price target
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- West Appoints Michel Lagarde to be President and Chief Executive Officer
- Amendment: West Pharmaceutical Services Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SVP, Proprietary Segment Campbell Shane Alden covered exercise/tax liability with 219 shares and converted options into 770 shares, increasing direct ownership by 881% to 613 units (SEC Form 4)
- SEC Form SD filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Pucci Paolo was granted 791 shares, increasing direct ownership by 7% to 11,854 units (SEC Form 4)
- Director Michels Douglas A was granted 791 shares, increasing direct ownership by 2% to 46,496 units (SEC Form 4)